Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2025-12-09 00:00:00 ET · period of report 2025-12-05 · accession 0001380177-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-09 | 2025-12-05 | EBS | Richard Ronald | Dir | S - Sale+OE | $11.97 | -22.0K | 98.4K | -18% | -$263.1K |
| D | 2025-12-09 | 2025-12-05 | EBS | Richard Ronald | Dir | F - Tax | $11.90 | -10.9K | 113.3K | -9% | -$129.3K |
| D | 2025-12-09 | 2025-12-05 | EBS | Richard Ronald | Dir | M - OptEx | $5.02 | +25.7K | 124.2K | +26% | +$129.3K |
| D | 2025-12-09 | 2025-12-05 | EBS | Richard Ronald | Dir | M - OptEx | $0.00 | -25.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-05 | S | D | 14,884 | $11.90 | 98,417 | D | — | — | (F4) The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97. |
| 2 | Common | Common Stock | 2025-12-05 | F | D | 10,864 | $11.90 | 113,301 | D | — | — | (F3) Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise. (F4) The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97. |
| 3 | Common | Common Stock | 2025-12-05 | M | A | 25,748 | $5.02 | 124,165 | D | — | — | |
| 4 | Common | Common Stock | 2025-12-05 | S | D | 7,100 | $12.11 | 98,417 | D | — | — | (F1) Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. (F2) The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12. |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-12-05 | M | D | 25,748 | $0.00 | 0 | D | $5.02 · — to 2031-05-22 | 25,748 Common Stock | (F5) Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025. |